PRINCIPLE: Serum lactate is a potentially useful biomarker to risk-stratify patients with severe sepsis; however, it is plausible that elevated serum lactate is simply a manifestation of clinically apparent organ dysfunction and/or shock (i.e., refractory hypotension). OBJECTIVE: To test whether the association between initial serum lactate level and mortality in patients presenting to the emergency department (ED) with severe sepsis is independent of organ dysfunction and shock. DESIGN: Single-center cohort study. The primary outcome was 28-day mortality and the risk factor variable was initial venous lactate (mmol/L), categorized as low (< 2), intermediate (2-3.9), or high (> or = 4). Potential covariates included age, sex, race, acute and chronic organ dysfunction, severity of illness, and initiation of early goal-directed therapy. Multivariable logistic regression analyses were stratified on the presence or absence of shock. SETTING: The ED of an academic tertiary care center from 2005 to 2007. PATIENTS: Eight hundred thirty adults admitted with severe sepsis in the ED. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Mortality at 28 days was 22.9% and median serum lactate was 2.9 mmol/L. Intermediate (odds ratio [OR] = 2.05, p = 0.024) and high serum lactate levels (OR = 4.87, p < 0.001) were associated with mortality in the nonshock subgroup. In the shock subgroup, intermediate (OR = 3.27, p = 0.022) and high serum lactate levels (OR = 4.87, p = 0.001) were also associated with mortality. After adjusting for potential confounders, intermediate and high serum lactate levels remained significantly associated with mortality within shock and nonshock strata. CONCLUSIONS: Initial serum lactate was associated with mortality independent of clinically apparent organ dysfunction and shock in patients admitted to the ED with severe sepsis. Both intermediate and high serum lactate levels were independently associated with mortality.
PRINCIPLE: Serum lactate is a potentially useful biomarker to risk-stratify patients with severe sepsis; however, it is plausible that elevated serum lactate is simply a manifestation of clinically apparent organ dysfunction and/or shock (i.e., refractory hypotension). OBJECTIVE: To test whether the association between initial serum lactate level and mortality in patients presenting to the emergency department (ED) with severe sepsis is independent of organ dysfunction and shock. DESIGN: Single-center cohort study. The primary outcome was 28-day mortality and the risk factor variable was initial venous lactate (mmol/L), categorized as low (< 2), intermediate (2-3.9), or high (> or = 4). Potential covariates included age, sex, race, acute and chronic organ dysfunction, severity of illness, and initiation of early goal-directed therapy. Multivariable logistic regression analyses were stratified on the presence or absence of shock. SETTING: The ED of an academic tertiary care center from 2005 to 2007. PATIENTS: Eight hundred thirty adults admitted with severe sepsis in the ED. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Mortality at 28 days was 22.9% and median serum lactate was 2.9 mmol/L. Intermediate (odds ratio [OR] = 2.05, p = 0.024) and high serum lactate levels (OR = 4.87, p < 0.001) were associated with mortality in the nonshock subgroup. In the shock subgroup, intermediate (OR = 3.27, p = 0.022) and high serum lactate levels (OR = 4.87, p = 0.001) were also associated with mortality. After adjusting for potential confounders, intermediate and high serum lactate levels remained significantly associated with mortality within shock and nonshock strata. CONCLUSIONS: Initial serum lactate was associated with mortality independent of clinically apparent organ dysfunction and shock in patients admitted to the ED with severe sepsis. Both intermediate and high serum lactate levels were independently associated with mortality.
Authors: Alexandra Ortego; David F Gaieski; Barry D Fuchs; Tiffanie Jones; Scott D Halpern; Dylan S Small; S Cham Sante; Byron Drumheller; Jason D Christie; Mark E Mikkelsen Journal: Crit Care Med Date: 2015-04 Impact factor: 7.598
Authors: H Ait-Oufella; J Joffre; P Y Boelle; A Galbois; S Bourcier; J L Baudel; D Margetis; M Alves; G Offenstadt; B Guidet; E Maury Journal: Intensive Care Med Date: 2012-04-14 Impact factor: 17.440
Authors: Cary Ma; Lourdes Cynthia Gunaratnam; Austin Ericson; Andrea L Conroy; Sophie Namasopo; Robert O Opoka; Michael T Hawkes Journal: Am J Trop Med Hyg Date: 2019-01 Impact factor: 2.345
Authors: Mark E Mikkelsen; David F Gaieski; Munish Goyal; Andrea N Miltiades; Jeffrey C Munson; Jesse M Pines; Barry D Fuchs; Chirag V Shah; Scarlett L Bellamy; Jason D Christie Journal: Chest Date: 2010-02-19 Impact factor: 9.410
Authors: Michael A Puskarich; Stephen Trzeciak; Nathan I Shapiro; Alan C Heffner; Jeffrey A Kline; Alan E Jones Journal: Resuscitation Date: 2011-06-23 Impact factor: 5.262
Authors: Stacey-Ann Whittaker; Mark E Mikkelsen; David F Gaieski; Sherine Koshy; Craig Kean; Barry D Fuchs Journal: Crit Care Med Date: 2013-04 Impact factor: 7.598
Authors: Vijay Krishnamoorthy; David B Hiller; Richard Ripper; Bocheng Lin; Stephen M Vogel; Douglas L Feinstein; Sarah Oswald; Leelach Rothschild; Priscilla Hensel; Israel Rubinstein; Richard Minshall; Guy L Weinberg Journal: Anesthesiology Date: 2012-10 Impact factor: 7.892
Authors: David H Jang; Clinton J Orloski; Shawn Owiredu; Frances S Shofer; John C Greenwood; David M Eckmann Journal: Shock Date: 2019-05 Impact factor: 3.454